

Appl. No. 09/805,099
Atty. Docket No. 8244MLS
Amdt. dated 1/17/06
Reply to Office Action of 1/11/06
Customer No. 27752

REMARKS/ARGUMENTS

Claims 1-11 and 15-80 are pending. Claim 1 has been amended to recite that the wrinkle removal composition used in the claimed method comprises a lithium salt. Basis is in the specification at page 41, beginning at line 18. Claims 2, 9 and 10 now recite further elements of the composition used in the method of Claim 1. Basis is in the original version of those claims, and at page 7, line 31 (silicone surfactant) and page 13, line 11 (particles). Claims 4 and 5 have been amended to refer back to "said" solvent, for clarity. It is submitted that all amendments are fully supported, and entry is requested.

Rejections Under 35 USC 112

The rejection of Claim 7 (Office Action page 2) is respectfully traversed. As the Examiner correctly notes, the claim specifically requires the "said composition" to have the specified flash point.

Clearly, this is in full alignment with the disclosure of the specification at page 59, line 10. Note, that the discussion at lines 1-9 is in regard to the solvent, but at line 10, when the flash point is specified, the disclosure denotes the "composition", not merely the solvent, as having the desired flash point.

In short, the wording of Claim 7 clearly defines the flash point as relating to the composition, as does the specification. Therefore, it is submitted that Claim 7 fully meets §112, and withdrawal of the rejection on this basis is requested.

Rejections Under 35 USC 102(e)

All claims stand rejected under §102(e) over U.S. 6,495,058 in view of The Merck Index, for reasons of record at pages 3-6 of the Office Action.

Applicants respectfully traverse all rejections, to the extent they may apply to the claims as now amended.

Claim 1 (and, perforce, all pending claims) recites the presence of a lithium salt in the composition used in the claimed method. It is submitted that, since nothing in '058 teaches the use of lithium salts in its disclosed compositions, '058 does not support a rejection under §102. Withdrawal of the rejection on this basis is requested.

Appl. No. 09/805,099
Atty. Docket No. 8244ML\$
Amdt. dated 1/17/06
Reply to Office Action of 1/11/06
Customer No. 27752

Supplemental Information Disclosure Statement


In view of the amendment of Claim 1 to recite the lithium salt, included herewith is a Form SB08 listing U.S. 4,069, 159; 4,233,212; 5,199,954; 5,252,285; 5,296,269; and 5,609,859, all cited at page 41 of the specification. It is requested that these United States patents be considered by the Examiner and made of record in the case.

In light of the foregoing, early and favorable action is requested.

Respectfully submitted,

THE PROCTER & GAMBLE COMPANY

By


Jerry J. Yetter

Date: January 27, 2006
Customer No. 27752

Registration No. 26,598
(513) 627-2996